This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Early Markers of Cognitive Change and Alzheimer s Disease

This study has been completed.
Johns Hopkins University
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ) Identifier:
First received: May 29, 2013
Last updated: June 30, 2017
Last verified: January 2, 2015


- The Baltimore Longitudinal Study of Aging (BLSA) is a long-term study of human aging. To see how the brain changes with age, researchers will study BLSA participants who are at least 60 years old. In particular, researchers are looking for early markers of possible Alzheimer's disease and other conditions that cause memory loss. To do so, they will give tests of memory and brain function, and stay in close contact with participants.


- To study cognitive changes that occur in normal aging and in people who develop memory problems.


- Individuals at least 60 years of age who are participating in the BLSA.


  • There are three parts to this study. These study procedures will be done under the usual BLSA guidelines.
  • Participants will take paper and pencil tests. The tests measure skills such as language, attention, memory, and problem solving. They will also ask questions about emotions and feelings.
  • Participants will give the name and phone number of a person who knows them well and sees them often. Researchers will ask this person to fill out questionnaires on the effects of aging on the participant. These questions will monitor the participant's memory and ability to function independently.
  • Participants will have regular phone calls between study visits. These calls will help to keep their information up to date.
  • Participants will continue on this study for as long as they are able to participate.

Alzheimer's Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ):

Primary Outcome Measures:
  • Identifying early makers of cognitive and Alzheimer s disease [ Time Frame: Ongoing ]
  • Characterizing risk factors which modify progression to these states [ Time Frame: Ongoing ]
  • Cognitive changes associated with other health factors [ Time Frame: Ongoing ]

Estimated Enrollment: 5000
Study Start Date: March 19, 2003
Estimated Study Completion Date: January 2, 2015
Primary Completion Date: June 16, 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Since the early 1960 s cognitive testing has been performed in conjunction with BLSA visits.

Prior to the mid-1980 s, the primary focus of these investigations was the natural history of age associated changes in memory and other cognitive functions. While a portion of the work of the Cognition Section still involves descriptive studies of cross-sectional and longitudinal effects of age on specific cognitive abilities, the cognitive testing program was refocused in the mid-1980 s to investigate early predictors of cognitive change, including risk and protective factors for cognitive impairment and Alzheimer s disease. In collaboration with Dr. Claudia Kawas, and more recently Dr. Richard O Brien of the Johns Hopkins Department of Neurology, the research program of the Cognition Section was expanded to ascertain incident cases of cognitive impairment and dementia, including home visit assessments for inactive participants. In addition, an autopsy program in collaboration with the Alzheimer s Disease Research Center (ADRC) at Johns Hopkins University was initiated. This collaboration has yielded a number of important findings including information on the incidence of Alzheimer s disease, and demonstrations that use of hormone replacement therapy in postmenopausal women and non-steroidal antiinflammatory drugs (NSAIDs) in older adults6 are associated with reductions in the risk for Alzheimer s disease in our community-dwelling BLSA participant sample.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

All BLSA participants 60 years of age and older are included and will receive cognitive evaluations on their BLSA visits.


Participants who are younger than 60 years old are excluded. Specialized testing procedures are adopted in the case of hearing or visual impairments

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01867346

United States, Maryland
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
National Institute on Aging (NIA)
Johns Hopkins University
Principal Investigator: Alan B Zonderman, Ph.D. National Institute on Aging (NIA)
  More Information

Responsible Party: National Institute on Aging (NIA) Identifier: NCT01867346     History of Changes
Other Study ID Numbers: 999903323
Study First Received: May 29, 2013
Last Updated: June 30, 2017

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ):
Cognitive Decline
Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 21, 2017